Disclosure AdB disclosures honoraria/institutional grants for advisory boards and/or educational activities (past 3 years): Roche, AstraZeneca/MSD, GSK/Tesaro, Clovis, Pfizer, Biocad, Genmab/Seattle Genetics, AMGEN and Zodiac; Founder/Chairman/Executive Board AGO Study Group; Co-Founder, Strategic Board and past president ENGOT; Past Chairman, Scientific Committee, and faculty of consensus conferences GCIG and ESGO/ESMO; and past/present member of national guideline committees Breast and Ovarian Cancer, and multiple further committees, working groups and editorial boards (e.g. J Clin Oncol, Gynecol Oncol, Int J Gynecol Cancer). KNM discloses advisory boards for Alkemeres, AstraZeneca, Aravive, Blueprint pharmaceuticals, Eisai, Elevar, GSK/Tesaro, Genentech/Roche, Hengrui, Immunogen, IMab, Merck, Mersana, Myriad, Mereo, Novartis, OncXerna, Onconova, Tarveda and VBL Therapeutics; receives research funding from PTC Therapeutics, Lilly, Merck and GSK/Tesaro; and serves as the Associate Director for GOG Partners and Chair of the NRG Ovarian Cancer Committee.